Pluristem (PSTI) Receives Positive Feedback from FDA on Phase III Trial of PLX-PAD in CLI
Tweet Send to a Friend
Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading developer of placenta-based cell therapy products, today announced that it ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
